A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2017 Planned number of patients changed from 46 to 30.
- 06 Apr 2016 New trial record